Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Bristol-Myers Squibb Sponsoring Cancer Research Network

T cell, in blue, a key component in the body's immune system (Lawrence Berkeley National Lab)

T cell, in blue, a key component in the body's immune system (Lawrence Berkeley National Lab)

Bristol-Myers Squibb Co., a pharmaceutical company in Princeton, New Jersey, has a new collaboration with academic researchers that aims to better understand the science of immuno-oncology, the harnessing of the body’s immune system to fight cancer. The network includes researchers from 10 universities and research institutes in the U.S. and Europe.

The company says its approach to immuno-oncology focuses on using the intelligence of the immune response to seek control of tumors. Understanding how the immune system detects and reacts to cancer cells, and how tumors can evade the immune response, says Bristol-Myers Squibb, is important in developing strategies to enhance the immune system’s ability to fight cancer.

Participating institutions in the Bristol-Myers Squibb network include:

– Clinica Universidad Navarra, Pamplona, Spain

– Dana-Farber Cancer Institute, Boston, Mass.

– Earle A. Chiles Research Institute (Providence Health & Services), Portland, Oregon

– Institut Gustave Roussy, Villejuif, France

– Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale, Naples, Italy

– Johns Hopkins Kimmel Cancer Center, Baltimore Maryland

– Memorial Sloan-Kettering Cancer Center, New York, New York

– Netherlands Cancer Institute, Amsterdam, Netherlands

– Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, U.K.

– University of Chicago, Chicago, Illinois

Bristol-Myers Squibb says it is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer. One objective of the collaboration is to encourage the translation of scientific research findings into clinical trials and, eventually, clinical practice. The company did not disclose financial or intellectual property details of the relationship with the institutions.

Read more:

*     *     *

1 comment to Bristol-Myers Squibb Sponsoring Cancer Research Network